Research
Energy balance
SGLT2 inhibitors promote weight loss and improve metabolic parameters (blood pressure, lipid profile, uric acid) by increasing urinary glucose excretion, resulting in an energy deficit of 240-320 kcal/day.
SGLT2 inhibitors help with weight loss by excreting glucose in urine, creating a daily calorie deficit of about 240-320 kcal. This can help reduce abdominal fat and improve blood pressure and lipids. However, weight loss tends to plateau, so combining the medication with lifestyle changes is important for long-term success.
GoodSupportsHIGH confidence
Excretion of 60–80 g of excess glucose corresponds to 240–320 kcal of energy loss from the body, promoting weight loss. Improvement of obesity/overweight, especially abdominal fat accumulation promotes amelioration of insulin resistance and results in improvement of metabolic parameters such as blood pressure, lipid profile, and serum uric acid level.
Why this rating
Based on meta-analysis of 45 clinical trials.
Source
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Yoshifumi Saisho · Diseases · 2020
DOI 10.3390/diseases8020014
narrative_reviewCited 130×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, primarily through hemodynamic effects (osmotic diuresis and natriuresis) rather than glucose-lowering.Strong
- SGLT2 inhibitors lower HbA1c by 0.6-0.8% without increasing hypoglycemia risk when used as monotherapy, but require dose adjustment of insulin/secretagogues when combined.Good
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →